


WHAT IS CLAIMED IS:

- A3* 1. A composition for the treatment of proliferative disorders,
2 comprising an antineoplastic agent and a compound having the formula:



- 3
4 and pharmaceutically acceptable salts thereof;
5 wherein

6 R is a member selected from the group consisting of hydrogen and
7 substituted or unsubstituted (C₁-C₁₀)alkyl; and

8 Ar is a member selected from the group consisting of substituted or
9 unsubstituted aryl and substituted or unsubstituted heteroary

- 1 2. A composition in accordance with claim 1, wherein said
2 antineoplastic agent is selected from the group consisting of DNA-alkylating agents,
3 antimetabolites, antifolates and other inhibitors of DNA synthesis, microtubule disruptors,
4 DNA intercalators, hormone agents, topoisomerase I/II inhibitors, DNA repair agents,
5 growth factor receptor kinase inhibitors, biological response modifiers, antiangiogenic
6 and antivascular agents, immunoconjugates and antisense oligonucleotides.

- 1 3. A composition in accordance with claim 1, wherein said
2 antineoplastic agent is selected from the group consisting of cyclophosphamide, BCNU,
3 busulfan, temozolomide, UFT, capecitabine, gemcitabine, cytarabine, imrosulfan,
4 piposulfan, benzodepa, carboquone, meturedopa, uredepa, altretamine,
5 triethylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide,
6 trimethylolmelamine, chlorambucil, estramustine, ifosfamide, novembrichin,
7 prednimustine, uracil mustard, dacarbazine, fluorouracil, methotrexate, mercaptoperine,
8 thioguanine, vinblastine, vincristine, vinorelbine, vindesine, etoposide, teniposide,
9 daunorubicin, doxorubicin, epirubicin, mitomycin, dactinomycin, daunomycin,
10 plicamycin, bleomycin, L-asparaginase, camptothecin, hydroxyurea, procarbazine,
11 mitotane, aminoglutethimide, tamoxifen, flutamide, mitoxantrone, paclitaxel, docetaxol,
12 and thiotepa.

13 4. A composition in accordance with claim 1, wherein said
14 antineoplastic agent is selected from the group consisting of doxorubicin, daunorubicin,
15 gemcitabine and paclitaxel.

16 5. A composition in accordance with claim 1, wherein said
17 antineoplastic agent is gemcitabine or paclitaxel.


1 6. A composition in accordance with claim 1, wherein R is hydrogen
2 or unsubstituted (C₁-C₄)alkyl.

1 7. A composition in accordance with claim 1, wherein Ar is a
2 substituted phenyl group.

1 8. A composition in accordance with claim 7, wherein said
2 substituents on said phenyl group are selected from the group consisting of halogen, (C₁-
3 C₄)alkoxy, (C₁-C₄)alkyl, -OPO₃H₂,


1 9. A composition in accordance with claim 8, wherein Ar represents a
2 member selected from the group consisting of

SEARCHED
INDEXED
MAILED
SEARCHED
INDEXED
MAILED




3

1 10. A composition in accordance with claim 1, wherein said compound
2 is selected from the group consisting of:




3



1 **11.** A method for the treatment of a proliferative disorder, comprising
2 administering to a subject in need of such treatment an effective amount of a composition
3 of claim 1.

1 **12.** A. method in accordance with claim 11, wherein said compound is
2 selected from the group consisting of:

3



4 **13.** A method in accordance with claim 12, wherein said antineoplastic
5 agent is selected from the group consisting of DNA-alkylating agents, antimetabolites,
6 antifolates and other inhibitors of DNA synthesis, microtubule disruptors, DNA
7 intercalators, hormone agents, topoisomerase I/II inhibitors, DNA repair agents, growth
8 factor receptor kinase inhibitors, biological response modifiers, antiangiogenic and
9 antivascular agents, immunoconjugates and antisense oligonucleotides.

1 **14.** A method in accordance with claim 12, wherein said antineoplastic
2 agent is selected from the group consisting of cyclophosphamide, BCNU, busulfan,
3 temozolamide, UFT, capecitabine, gemcitabine, cytarabine, imrosulfan, piposulfan,
4 benzodepa, carboquone, meturedopa, uredepa, altretamine, triethylenemelamine,
5 triethylenephosphoramide, triethylenethiophosphoramide, trimethylolmelamine,
6 chlorambucil, estramustine, ifosfamide, novembrichin, prednimustine, uracil mustard,
7 dacarbazine, fluorouracil, methotrexate, mercaptoperine, thioguanine, vinblastine,


8 vincristine, vinorelbine, vindesine, etoposide, teniposide, daunorubicin, doxorubicin,
9 epirubicin, mitomycin, dactinomycin, daunomycin, plicamycin, bleomycin, L-
10 asparaginase, camptothecin, hydroxyurea, procarbazine, mitotane, aminoglutethimide,
11 tamoxifen, flutamide, mitoxantrone, paclitaxel, docetaxol, and thiotepa.

12 15. A method in accordance with claim 12, wherein said antineoplastic
13 agent is selected from the group consisting of doxorubicin, daunorubicin, gemcitabine
14 and paclitaxel.

15 16. A method in accordance with claim 12, wherein said antineoplastic
16 agent is gemcitabine or paclitaxel.

17 *AS SCH* 17. A method for the treatment of a proliferative disorder, comprising
18 administering to a subject in need of such treatment:

- 19 i) a first amount of an antineoplastic agent; and
20 ii) a second amount of a compound of formula:




21
22 and pharmaceutically acceptable salts thereof; wherein

23 R is a member selected from the group consisting of hydrogen and
24 substituted or unsubstituted (C₁-C₁₀)alkyl; and


25 Ar is a member selected from the group consisting of substituted or
26 unsubstituted aryl and substituted or unsubstituted heteroaryl;

27 wherein said first amount and said second amount, in combination, are
28 effective to treat said proliferative disorder

1 18. A method in accordance with claim 17, wherein said compound is
2 selected from the group consisting of



and



3

4

5 **19.** A method in accordance with claim 18, wherein said antineoplastic
 6 agent is selected from the group consisting of DNA-alkylating agents, antimetabolites,
 7 antifolates and other inhibitors of DNA synthesis, microtubule disruptors, DNA
 8 intercalators, hormone agents, topoisomerase I/II inhibitors, DNA repair agents, growth
 9 factor receptor kinase inhibitors, biological response modifiers, antiangiogenic and
 10 antivascular agents, immunoconjugates and antisense oligonucleotides.

1 **20.** A method in accordance with claim 18, wherein said antineoplastic
 2 agent is selected from the group consisting of cyclophosphamide, BCNU, busulfan,
 3 temozolomide, UFT, capecitabine, gemcitabine, cytarabine, imrosulfan, piposulfan,
 4 benzodepa, carboquone, meturedopa, uredepa, altretamine, triethylenemelamine,
 5 triethylenephosphoramide, triethylenethiophosphoramide, trimethylolmelamine,
 6 chlorambucil, estramustine, ifosfamide, novembrichin, prednimustine, uracil mustard,
 7 dacarbazine, fluorouracil, methotrexate, mercaptopurine, thioguanine, vinblastine,
 8 vincristine, vinorelbine, vindesine, etoposide, teniposide, daunorubicin, doxorubicin,
 9 epirubicin, mitomycin, dactinomycin, daunomycin, plicamycin, bleomycin, L-
 10 asparaginase, camptothecin, hydroxyurea, procarbazine, mitotane, aminoglutethimide,
 11 tamoxifen, flutamide, mitoxantrone, paclitaxel, docetaxol, and thiotepa.

12 **21.** A method in accordance with claim 18, wherein said antineoplastic
 13 agent is selected from the group consisting of doxorubicin, daunorubicin, gemcitabine
 14 and paclitaxel.

15 **22.** A method in accordance with claim 18, wherein said antineoplastic
16 agent is gemcitabine or paclitaxel.

17

18 **23.** A method in accordance with claim 18, wherein said antineoplastic
19 agent is administered prior to said compound.

20

21 **24.** A method in accordance with claim 18, wherein said antineoplastic
22 agent is administered after said compound.

23

24 **25.** A method in accordance with claim 18, wherein said antineoplastic
25 agent is administered simultaneously with said compound.